Argenx Se (ARGX) Accounts Payables (2015 - 2026)
Argenx Se's (ARGX) quarterly Accounts Payables came in at $1.5 billion in Q2 2026, down 99.85% YoY from $1016.2 billion in Q2 2025, and up 19.57% on a QoQ basis from $1.3 billion in Q4 2025.
Argenx Se (ARGX) Accounts Payables (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Accounts Payables data on file, last reported at $1.5 billion in Q2 2026.
- Quarterly Accounts Payables fell 99.85% year-over-year to $1.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.5 billion (down 99.85% YoY) and the FY2025 annual result came in at $1.3 billion, up 94.93% from the prior year.
- Accounts Payables climbed to $1.5 billion in Q2 2026, from $1.3 billion in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $1016.2 billion in Q2 2025 to a low of $257.7 million in Q2 2022.
- A 5-year average of $113.5 billion and a median of $479.8 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2025 — Accounts Payables jumped 211675.45% — and 2026, when it plunged 99.85%.
- Tracing ARGX's Accounts Payables over 5 years: stood at $295.7 million in 2022, then soared by 40.02% to $414.0 million in 2023, then jumped by 57.0% to $650.0 million in 2024, then soared by 94.93% to $1.3 billion in 2025, then gained by 19.57% to $1.5 billion in 2026.
- The last three Accounts Payables figures came in at $1.5 billion (Q2 2026), $1.3 billion (Q4 2025), and $1016.2 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 25.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.52 Bn |
| Dec 31, 2025 | 1.27 Bn |
| Jun 30, 2025 | 1,016.16 Bn |
| Dec 31, 2024 | 649.99 Mn |
| Jun 30, 2024 | 479.83 Mn |
| Dec 31, 2023 | 414.01 Mn |
| Jun 30, 2023 | 309.99 Mn |
| Dec 31, 2022 | 295.68 Mn |
| Jun 30, 2022 | 257.69 Mn |
| Dec 31, 2021 | 293.42 Mn |
| Jun 30, 2021 | 239.44 Mn |
| Dec 31, 2020 | 267.39 Mn |
| Jun 30, 2020 | 140.82 Mn |
| Dec 31, 2019 | 94.42 Mn |
| Jun 30, 2019 | 61.88 Mn |
| Dec 31, 2018 | 42.31 Mn |
| Jun 30, 2018 | 25.73 Mn |
| Dec 31, 2017 | 18.00 Mn |
| Jun 30, 2017 | 14.37 Mn |
| Dec 31, 2016 | 13.16 Mn |